Argenica Therapeutics (ASX:AGN) has spent 2026 methodically building the clinical and regulatory case for its lead neuroprotective candidate, ARG-007, and the pace of progress has kept the Perth-based biotech on the radar of investors who follow early-stage drug developers on the ASX. The company …
EBR Systems (ASX:EBR) is moving deeper into the commercialisation phase of its WiSE CRT System, with a fresh manufacturing milestone adding another component to its scale-up strategy. The US-based, ASX-listed medical technology company has developed a wireless endocardial pacing system designed for heart-failure patients …
Immutep (ASX:IMM) enters the second half of 2026 as a clinical-stage immuno-oncology company at a crossroads, after a major trial setback reshaped its pipeline narrative. The developer of eftilagimod alfa, an antigen-presenting-cell activator targeting the LAG-3 pathway, has spent the year absorbing a disappointment …
Botanix Pharmaceuticals (ASX:BOT) has moved from a development-stage biotech into an early commercial company, and its June-quarter results gave investors their clearest look yet at how the US launch of Sofdra is tracking after roughly its first full year on the market. Sofdra, a …
Trajan Group Holdings (ASX:TRJ) is one of those ASX names that rarely grabs headlines yet sits in an interesting corner of the market: analytical science and precision measurement. The Melbourne-based company designs and manufactures consumables, devices and instruments used in laboratories across life sciences, …
ImpediMed (ASX:IPD) is trying to prove that a well-established clinical technology can finally translate into a self-sustaining commercial business. The Brisbane-based medical-technology company makes SOZO, a bioimpedance spectroscopy device used to detect and monitor conditions including secondary lymphoedema, particularly in cancer survivors. After years …
INOVIQ (ASX:IIQ) continues advancing its life-sciences platform focused on exosome-based diagnostics and therapeutic applications, with the company targeting opportunities in cancer detection and precision medicine.
Argenica Therapeutics (ASX:AGN) continues developing its neuroprotection platform, with the company focused on advancing ARG-007 (xaranetide) across potential applications in stroke and traumatic brain injury. The Perth-based biotechnology company is working to translate its scientific research into therapies targeting conditions where significant unmet medical …
Racura Oncology (ASX:RAC) continues advancing its cancer therapeutics strategy as the company moves its lead asset RC220 through early-stage clinical development. Formerly known as Race Oncology, the company is focused on developing treatments targeting areas of unmet need across oncology.
Trajan Group (ASX:TRJ) continues working through a business reset aimed at improving profitability and strengthening its position in the analytical science sector. The Victorian-based company supplies scientific instruments, consumables and related technologies used across healthcare, environmental and industrial applications.